Members of Innovative Medicines Canada (IMC), the lobby group for
Read moreWhat Big Pharma pays your doctor
Home » Medications »
Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics,
Read moreFDA Approves Qbrexza
MENLO PARK, Calif., June 29, 2018 (GLOBE NEWSWIRE) — Dermira,
Read moreFDA Approves Aristada Initio
DUBLIN, July 2, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS)
Read moreHTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
SAN DIEGO–(BUSINESS WIRE)–Jun. 21, 2018– Heron Therapeutics, Inc. (NASDAQ: HRTX),
Read moreFDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations
On June 27, 2018, the Food and Drug Administration approved
Read moreThe creeping problem of drug shortages
Dozens of drugs are suddenly unavailable every year. In Canada,
Read moreAllergan’s Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
DUBLIN, June 11, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN),
Read moreParatek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
BOSTON, June 11, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc.
Read moreAMA: docs declare drug shortages public health emergency
(HealthDay)—At the annual meeting of the American Medical Association (AMA),
Read more